chufangao/CTO huggingface dataset:
Clinical trial NCT03824808: Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery
Official title: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy
Sponsor: University of Missouri-Columbia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Challenges with recruitment of surgical research subjects in the target population.
Enrollment: 21.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-26
Primary completion date: 2020-03-26
Completion date: 2020-03-26
Baseline population: 11 patients were randomized into the treatment group, while 10 patients were randomized to the control group. Investigators were blinded to the randomization.
Plan to share individual participant data: NO
Clinical trial NCT03805841: Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Official title: Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
Acronym: RAIN
Sponsor: Rain Oncology Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: enrollment pause
Enrollment: 41.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-13
Primary completion date: 2021-04-09
Completion date: 2021-04-23
Plan to share individual participant data: NO
IPD sharing description: No Plan
Clinical trial NCT04899232: Antithrombin III in Infectious Disease Caused by COVID-19
Official title: Antithrombin III (AT3) in Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)/ Coronavirus Disease of 2019 (COVID-19)
Sponsor: University of Miami (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: There are fewer potential patients and an early conclusion of the study would be beneficial in an attempt to finish in a reasonable time and keep the cohorts homogenous.
Enrollment: 52.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-07-06
Primary completion date: 2022-03-31
Completion date: 2022-03-31
Limitations and caveats: With decreased Coronavirus disease of 2019 (COVID-19) cases, enrollment slowed leading to the early termination of the trial; the target number of 75 enrolled patients was not reached. Hesitancy to participate in the trial was noted.
Plan to share individual participant data: NO
Clinical trial NCT05028751: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Official title: A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination With the FLT3 Inhibitor Gilteritinib, in Patients With FLT3-mutated Relapsed or Refractory AML
Sponsor: Kronos Bio (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 24.0 (ACTUAL)
Number of arms: 4.0
Start date: 2022-08-05
Primary completion date: 2024-04-09
Completion date: 2024-04-09
Baseline population: Safety Population: Consisted of all participants who received ≥ 1 dose of either study drug and had at least 1 on-treatment safety-related observation.
Limitations and caveats: In light of the Sponsor's decision to terminate the trial at completion of Phase 1b, all analyses were restricted to results from Phase 1b participants only. Phase 2 was not enrolled.
Plan to share individual participant data: NO
Clinical trial NCT00288080: Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
Official title: A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs AS and 3DCTR/IMRT Followed by Chemotherapy With Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer
Sponsor: Radiation Therapy Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 612.0 (ACTUAL)
Number of arms: 2.0
Start date: 2005-12-31
Primary completion date: 2014-04-30
Completion date: 2022-05-20
Baseline population: Eligible patients who have not withdrawn consent.
Limitations and caveats: Due to insufficient number of events, local control analysis was not conducted.
Clinical trial NCT04315181: Prescription Medication Interactions
Official title: Prescription Medications: Pharmacodynamics and Interaction Effects
Sponsor: University of Kentucky (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 11.0 (ACTUAL)
Number of arms: 9.0
Start date: 2019-03-25
Primary completion date: 2023-05-06
Completion date: 2023-05-06
Baseline population: One participant did not complete the study. They were non-responsive to the drug conditions and was discharged.
Plan to share individual participant data: NO
IPD sharing description: We have no plans to share individual participant data with other researchers.
Clinical trial NCT03219866: Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
Official title: Preliminary Study for Comparison of Triple Therapy Nebulizer Versus Dry Powdered Inhaler for Care Transitions in COPD
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Lower enrollment than Sponsor expected - Sponsor stopped study
Enrollment: 40.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-03
Primary completion date: 2020-04-01
Completion date: 2020-04-01
Plan to share individual participant data: NO
Clinical trial NCT02292238: Benfotiamine in Alzheimer's Disease: A Pilot Study
Official title: Benfotiamine in Alzheimer's Disease: A Pilot Study
Acronym: Benfotiamine
Sponsor: Burke Medical Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 71.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-02-15
Primary completion date: 2020-07-20
Completion date: 2020-09-08
Baseline population: 1 subject on the placebo arm was excluded from analysis due to taking benfotiamine from a commercial vendor.
Clinical trial NCT04040686: HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02
Official title: Technetium-99m Labeled Anti-HER2 sdAb (99m-Tc-NM-02) for HER2 Expression Detection in Breast Cancer
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-07-29
Primary completion date: 2021-12-31
Completion date: 2022-03-30
Clinical trial NCT02734615: Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Official title: A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 199.0 (ACTUAL)
Number of arms: 7.0
Start date: 2016-06-14
Primary completion date: 2021-09-13
Completion date: 2021-09-13
Plan to share individual participant data: NO
Clinical trial NCT03477162: Metformin Pharmacology in Human Cancers: A Proof of Principle Study
Official title: Metformin Pharmacology in Human Cancers
Sponsor: Dartmouth-Hitchcock Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-15
Primary completion date: 2021-11-30
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT04004221: Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
Official title: A Single-Arm, Multicenter Phase 2 Study of BGB-A317 in Patients With Previously Treated PD-L1+ Locally Advanced or Metastatic Urothelial Bladder Cancer
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 113.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-16
Primary completion date: 2019-09-16
Completion date: 2021-03-11
Baseline population: Safety Analysis Set includes all participants who received any dose of Tislelizumab
Plan to share individual participant data: YES
IPD sharing description: Upon request, and subject to certain criteria, conditions, and exceptions, BeiGene will provide access to individual de-identified participant data from BeiGene-sponsored global interventional clinical studies conducted for medicines for indications that have been approved or in programmes that have been terminated. BeiGene will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data requests can be submitted to medicalinformation@beigene.com.
Clinical trial NCT02765165: Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Official title: A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination With Lomustine (CCNU) in Subjects With Advanced Solid Tumors, With Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects With Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Sponsor: Proximagen, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Business reasons not related to safety
Enrollment: 26.0 (ACTUAL)
Number of arms: 5.0
Start date: 2016-04-30
Primary completion date: 2020-07-01
Completion date: 2020-07-01
Limitations and caveats: Small cohort sample size. Heterogenous solid tumor types.
Clinical trial NCT03451773: M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
Official title: A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Study was closed after one treatment related death.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-17
Primary completion date: 2020-05-05
Completion date: 2020-05-05
Plan to share individual participant data: NO
Clinical trial NCT03757910: Brain Imaging in the Diabetes Prevention Program Outcomes Study
Official title: Amyloid Brain Positron Emission Tomography (PET) Imaging With 11C-PIB and Tau PET Imaging With 18F-MK-6240 in the Diabetes Prevention Program Outcomes Study.
Acronym: DPPOS-Brain
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Difficulty recruiting due to the COVID-19 pandemic and end of funding
Enrollment: 5.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-01
Primary completion date: 2023-01-31
Completion date: 2023-01-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT00676715: A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Official title: Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
Sponsor: Genentech, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 220.0 (ACTUAL)
Number of arms: 4.0
Start date: 2008-07-17
Primary completion date: 2012-03-09
Completion date: 2023-11-08
Baseline population: The safety population included all participants who received any study drug and underwent at least one assessment of safety.
Clinical trial NCT03891173: A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
Official title: A Phase II, Open-Label, Randomized Study Immunoconjugate L-DOS47 in Combination With Vinorelbine/Cisplatin Versus Vinorelbine/Cisplatin Alone in Patients With Lung Adenocarcinoma
Sponsor: Helix BioPharma Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study was halted at this time due to other budgetary priorities. Completion of reporting has been delayed first due to covid restrictions and more recently due to war in Ukraine.
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-19
Primary completion date: 2020-05-22
Completion date: 2020-05-22
Plan to share individual participant data: NO
Clinical trial NCT04660643: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
Official title: Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Acronym: SURMOUNT-4
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 783.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-03-29
Primary completion date: 2023-04-25
Completion date: 2023-05-18
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04673786: A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
Official title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Moderate to Severe Plaque Psoriasis
Sponsor: Celltrion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 509.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-11
Primary completion date: 2021-08-04
Completion date: 2022-05-12
Limitations and caveats: Due to the conflict in Ukraine, sponsor provided guideline for exceptional allowance regarding visit window and study assessments (only EOS visit was affected) in order to ensure patients' safety and the robustness and integrity of data.
Clinical trial NCT05532046: A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
Official title: A Phase 1b Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 4 Weeks Treatment With BAY 2413555 in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices
Acronym: REMOTE-HF
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to new preclinical findings in a chronic toxicology study.
Enrollment: 22.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-09-20
Primary completion date: 2023-03-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Clinical trial NCT03212716: Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.
Official title: Validation of the Efficiency of Molecules Reproposed on the Basis of Their Cellular Transcriptomic Signature, Antagonist of the Signature Determined in Infection Due to Virus Influenza A.
Acronym: FLUNEXT
Sponsor: University Hospital, Lille (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: rate of inclusion and study affected by covid-19 epidemic
Enrollment: 85.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-23
Primary completion date: 2022-05-04
Completion date: 2022-05-04
Clinical trial NCT00326898: Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
Official title: ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Acronym: ASSURE
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1943.0 (ACTUAL)
Number of arms: 3.0
Start date: 2006-04-24
Primary completion date: 2015-08-27
Completion date: 2021-09-01
Baseline population: All randomized patients
Clinical trial NCT01389024: Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
Official title: Hydroxyurea to Prevent Central Nervous System (CNS) Complications of Sickle Cell Disease in Children
Acronym: HUPrevent
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-08-16
Primary completion date: 2022-05-24
Completion date: 2022-05-24
Baseline population: Baseline characteristics data was not collected for non-randomized subjects.
Limitations and caveats: Interpretation is limited by small sample size.
Plan to share individual participant data: NO
Clinical trial NCT03759665: N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
Official title: Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study
Sponsor: IntraBio Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-07
Primary completion date: 2023-01-09
Completion date: 2023-01-09
Limitations and caveats: This study was ongoing during the COVID-19 pandemic, and the conduct of this study was impacted by the COVID-19 pandemic.
Clinical trial NCT05119712: Terbinafine Treatment of Axial Spondyloarthropathy
Official title: Terbinafine Treatment of Axial Spondyloarthropathy
Acronym: FUN
Sponsor: Oregon Health and Science University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Study stopped due to poor recruitment.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-09
Primary completion date: 2023-10-15
Completion date: 2024-10-15
Plan to share individual participant data: NO
IPD sharing description: There is no plan to share IPD with other researchers.
Clinical trial NCT03585270: Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
Official title: A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)
Acronym: REACT
Sponsor: Idorsia Pharmaceuticals Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 409.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-02-03
Primary completion date: 2022-06-13
Completion date: 2022-11-18
Baseline population: Full Analysis Set
Plan to share individual participant data: NO
Clinical trial NCT02460874: Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)
Official title: A Pilot Study and Phase II Double Blind Placebo Controlled Randomized Trial Examining the Safety and Efficacy of Glyburide as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-08-16
Primary completion date: 2021-05-19
Completion date: 2021-05-19
Baseline population: terminated early
Clinical trial NCT03894618: SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Official title: Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With Advanced Solid Tumors or Lymphomas
Sponsor: Shattuck Labs, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 49.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-03-26
Primary completion date: 2023-05-04
Completion date: 2023-05-04
Clinical trial NCT04317040: Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
Official title: A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment
Acronym: SAC-COVID
Sponsor: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 234.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-24
Primary completion date: 2020-10-20
Completion date: 2020-10-20
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT02026297: Tranexamic Acid and Thromboelastography During Cesarean Delivery
Official title: The Influence of Prophylactic Tranexamic Acid on Thromboelastography During Cesarean Delivery: A Randomized, Double-Blind, Placebo-Controlled Trial
Acronym: TA TEG
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: funding and manpower unavailable, completion within a reasonable timeframe not possible.
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-07-31
Primary completion date: 2015-07-31
Completion date: 2020-02-21
Baseline population: Patients scheduled for elective cesarean delivery with low risk for postpartum hemorrhage.